Literature DB >> 22321467

Management of covert hepatic encephalopathy.

Kevin D Mullen1, Ravi K Prakash.   

Abstract

Employability, driving capacity, and many domains of health-related quality of life are reduced in patients with minimal hepatic encephalopathy (HE). Moreover, once minimal HE is identified, more than 50% of patients develop overt HE within 30 months. Now that minimal HE has been shown to be associated with consequences, more studies are needed to assess the cost effectiveness to treat it. This article discusses the issues regarding diagnosis and management of minimal HE, now called "Covert HE."
Copyright © 2012. Published by Elsevier Inc.

Entities:  

Mesh:

Year:  2012        PMID: 22321467     DOI: 10.1016/j.cld.2011.12.006

Source DB:  PubMed          Journal:  Clin Liver Dis        ISSN: 1089-3261            Impact factor:   6.126


  3 in total

1.  Minimal hepatic encephalopathy in children with liver cirrhosis: diffusion-weighted MR imaging and proton MR spectroscopy of the brain.

Authors:  Ahmed Abdel Khalek Abdel Razek; Ahmed Abdalla; Amany Ezzat; Ahmed Megahed; Tarek Barakat
Journal:  Neuroradiology       Date:  2014-07-25       Impact factor: 2.804

2.  Validation of EncephalApp, Smartphone-Based Stroop Test, for the Diagnosis of Covert Hepatic Encephalopathy.

Authors:  Jasmohan S Bajaj; Douglas M Heuman; Richard K Sterling; Arun J Sanyal; Muhammad Siddiqui; Scott Matherly; Velimir Luketic; R Todd Stravitz; Michael Fuchs; Leroy R Thacker; HoChong Gilles; Melanie B White; Ariel Unser; James Hovermale; Edith Gavis; Nicole A Noble; James B Wade
Journal:  Clin Gastroenterol Hepatol       Date:  2014-05-17       Impact factor: 11.382

3.  Cerebral Hemodynamics and Cognitive Function in Cirrhotic Patients with Hepatic Encephalopathy.

Authors:  Yuqing Zhou; Qian Dong; Rong Zhang; Shunfeng Zhou; Linqiang Li; Keran Cheng; Rui Kong; Qiang Yu; Shizan Xu; Jingjing Li; Sainan Li; Jiao Feng; Liwei Wu; Tong Liu; Xiya Lu; Kan Chen; Yujing Xia; Jie Lu; Yingqun Zhou; Chuanyong Guo
Journal:  Gastroenterol Res Pract       Date:  2016-12-21       Impact factor: 2.260

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.